Literature DB >> 28277363

Fetoscopic Open Neural Tube Defect Repair: Development and Refinement of a Two-Port, Carbon Dioxide Insufflation Technique.

Michael A Belfort1, William E Whitehead, Alireza A Shamshirsaz, Zhoobin H Bateni, Oluyinka O Olutoye, Olutoyin A Olutoye, David G Mann, Jimmy Espinoza, Erin Williams, Timothy C Lee, Sundeep G Keswani, Nancy Ayres, Christopher I Cassady, Amy R Mehollin-Ray, Magdalena Sanz Cortes, Elena Carreras, Jose L Peiro, Rodrigo Ruano, Darrell L Cass.   

Abstract

OBJECTIVE: To describe development of a two-port fetoscopic technique for spina bifida repair in the exteriorized, carbon dioxide-filled uterus and report early results of two cohorts of patients: the first 15 treated with an iterative technique and the latter 13 with a standardized technique.
METHODS: This was a retrospective cohort study (2014-2016). All patients met Management of Myelomeningocele Study selection criteria. The intraoperative approach was iterative in the first 15 patients and was then standardized. Obstetric, maternal, fetal, and early neonatal outcomes were compared. Standard parametric and nonparametric tests were used as appropriate.
RESULTS: Data for 28 patients (22 endoscopic only, four hybrid, two abandoned) are reported, but only those with a complete fetoscopic repair were analyzed (iterative technique [n=10] compared with standardized technique [n=12]). Maternal demographics and gestational age (median [range]) at fetal surgery (25.4 [22.9-25.9] compared with 24.8 [24-25.6] weeks) were similar, but delivery occurred at 35.9 (26-39) weeks of gestation with the iterative technique compared with 39 (35.9-40) weeks of gestation with the standardized technique (P<.01). Duration of surgery (267 [107-434] compared with 246 [206-333] minutes), complication rates, preterm prelabor rupture of membranes rates (4/12 [33%] compared with 1/10 [10%]), and vaginal delivery rates (5/12 [42%] compared with 6/10 [60%]) were not statistically different in the iterative and standardized techniques, respectively. In 6 of 12 (50%) compared with 1 of 10 (10%), respectively (P=.07), there was leakage of cerebrospinal fluid from the repair site at birth. Management of Myelomeningocele Study criteria for hydrocephalus-death at discharge were met in 9 of 12 (75%) and 3 of 10 (30%), respectively, and 7 of 12 (58%) compared with 2 of 10 (20%) have been treated for hydrocephalus to date. These latter differences were not statistically significant.
CONCLUSION: Fetoscopic open neural tube defect repair does not appear to increase maternal-fetal complications as compared with repair by hysterotomy, allows for vaginal delivery, and may reduce long-term maternal risks. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02230072.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28277363     DOI: 10.1097/AOG.0000000000001941

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  21 in total

Review 1.  Imaging of open spinal dysraphisms in the era of prenatal surgery.

Authors:  Usha D Nagaraj; Beth M Kline-Fath
Journal:  Pediatr Radiol       Date:  2020-11-30

2.  Subsequent pregnancy outcomes after open maternal-fetal surgery for myelomeningocele.

Authors:  William H Goodnight; Ozan Bahtiyar; Kelly A Bennett; Stephen P Emery; J B Lillegard; Allan Fisher; Ruth Goldstein; Jillian Jatres; Foong-Yen Lim; Laurence McCullough; Ueli Moehrlen; Julie S Moldenhauer; Anita J Moon-Grady; Rodrigo Ruano; Daniel W Skupski; Elizabeth Thom; Marjorie C Treadwell; KuoJen Tsao; Amy J Wagner; Lindsay N Waqar; Michael Zaretsky
Journal:  Am J Obstet Gynecol       Date:  2019-03-15       Impact factor: 8.661

Review 3.  Regenerative Prophylaxis In Utero.

Authors:  Rodrigo Ruano; Elizabeth Ann L Enninga; Paola E Brana Rivera; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2018-11-11       Impact factor: 6.875

4.  Fetoscopic techniques for prenatal covering of gastroschisis in an ovine model are technically demanding and do not lead to permanent anchoring on the fetus until the end of gestation.

Authors:  Robert Bergholz; Thomas Krebs; Birte Cremieux; Carla Georgi; Felipe Fromm; Michael Boettcher; Thomas Andreas; Bastian Tiemann; Katharina Wenke; Konrad Reinshagen; Kurt Hecher
Journal:  Surg Endosc       Date:  2020-02-18       Impact factor: 4.584

5.  Low level myelomeningoceles: do they need prenatal surgery?

Authors:  Pierre-Aurelien Beuriat; Isabelle Poirot; Frederic Hameury; Delphine Demede; Kieron J Sweeney; Alexandru Szathmari; Federico Di Rocco; Carmine Mottolese
Journal:  Childs Nerv Syst       Date:  2019-03-27       Impact factor: 1.475

6.  Care Levels for Fetal Therapy Centers.

Authors:  Ahmet A Baschat; Sean B Blackwell; Debnath Chatterjee; James J Cummings; Stephen P Emery; Shinjiro Hirose; Lisa M Hollier; Anthony Johnson; Sarah J Kilpatrick; Francois I Luks; M Kathryn Menard; Lawrence B McCullough; Julie S Moldenhauer; Anita J Moon-Grady; George B Mychaliska; Michael Narvey; Mary E Norton; Mark D Rollins; Eric D Skarsgard; KuoJen Tsao; Barbara B Warner; Abigail Wilpers; Greg Ryan
Journal:  Obstet Gynecol       Date:  2022-05-02       Impact factor: 7.623

Review 7.  Resuscitation decisions in fetal myelomeningocele repair should center on parents' values: a counter analysis.

Authors:  Stephanie K Kukora; Jessica T Fry
Journal:  J Perinatol       Date:  2022-04-07       Impact factor: 3.225

Review 8.  Fetal myelomeningocele repair: a narrative review of the history, current controversies and future directions.

Authors:  Kaeli J Yamashiro; Diana L Farmer
Journal:  Transl Pediatr       Date:  2021-05

Review 9.  Understanding Sociodemographic Disparities in Maternal-Fetal Surgery Study Participation.

Authors:  Abigail Wilpers; Anna Y Lynn; Barbara Eichhorn; Amy B Powne; Megan Lagueux; Janene Batten; Mert Ozan Bahtiyar; Cary P Gross
Journal:  Fetal Diagn Ther       Date:  2022-03-10       Impact factor: 2.208

10.  A study to assess global availability of fetal surgery for myelomeningocele.

Authors:  Adalina Sacco; Lynn Simpson; Jan Deprest; Anna L David
Journal:  Prenat Diagn       Date:  2018-11-20       Impact factor: 3.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.